The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials

Clinical and Translational Oncology

Volumn 17, Issue 5, 2015, Pages 371-377

  Zhang, L L ^a   Cao, F F ^a   Wang, Y ^a   Meng, F L ^a   Zhang, Y ^a   Zhong, D S ^a   Zhou, Q H ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Meta analysis; Non small cell lung cancer; PKC inhibitor; RCT

Indexed keywords

PROTEIN KINASE C INHIBITOR; ANTINEOPLASTIC AGENT; APRINOCARSEN; ENZASTAURIN; INDOLE DERIVATIVE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; DIARRHEA; DRUG EFFICACY; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY FAILURE; LEUKOPENIA; META ANALYSIS; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; LUNG NEOPLASMS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84928333225     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1241-3     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
2. D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E, et al. Metastatic non-small-cell lung cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii56–vii64.
3. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277–83.
4. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 2003;63(4):780–6.
5. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res. 2007;55(6):477–86.
6. Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, et al. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003;39(2):191–6.
7. Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res. 2007;13(9):2667–74.
8. Mack PC, Gandara DR, Lau AH, Lara PN Jr, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003;51(4):337–48.
9. Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, Faivre S, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol. 2004;15(2):316–23.
10. Vansteenkiste J, Canon JL, Riska H, Pirker R, Peterson P, John W, et al. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs. 2005;23(3):263–9.
11. Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2010;5(12):1963–9.
12. Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, et al. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013;24(10):1079–83.
13. Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen V, et al. Enzastaurin, a protein kinase C-beta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. J Clin Oncol. 2006;24:612s (abstract 13138).
14. Giovannetti E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond J, et al. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets. 2010;11(1):12–28.
15. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24:4092–9.
16. Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:6086–93.
17. Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, et al. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplat in, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol. 2010;5(11):1815–20.
18. Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(3):369–75.
19. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006;24(9):1428–34.
20. Lee SH, Chen T, Zhou J, Hofmann J, Bepler G. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer. Clin Lung Cancer. 2010;11:169–75.
21. Ritch P, Rudin CM, Bitran JD, Edelman MJ, Makalinao A, Irwin D, et al. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2006;52(2):173–80.
22. Körner A, Mudduluru G, Manegold C, Allgayer H. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer. 2010;103(6):802–11.
23. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, et al. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010;9(10):2814–24.
24. Regala RP, Thompson EA, Fields AP. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res. 2008;68(14):5888–95.
25. Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014;25(2):139–51.
26. Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxed or pemetrexed with of without cetuximab in recurrent or progressive non-small cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013;14(13):1326–36.
27. Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non–small-cell lung cancer, north central cancer treatment group study N0528. J Thorac Oncol. 2013;8(1):79–88.
28. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost. 2010;8(3):454–62.
29. Fisher MD, D’Orazio A. Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer. 2000;2(1):21–2.
30. Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, et al. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012;7(11):1713–21.